Home > Protocol Summaries: Compounds > GSK2485852 Protocol Summaries: GSK2485852 GSKStudy ID Phase Title Status 115040 phase 1 A Randomized, Double Blind, Dose Escalation, Fusion, First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects Terminated
